

Noxopharm collaborator given \$1.45 million grant to fund inflammation research

Hudson Institute of Medical Research has been awarded a Victorian Government grant to fund research into novel therapeutics that block inflammation associated with long COVID.



**Jonathan
Jackson**

20:19 Tue 21 Jun 2022

[Noxopharm Ltd \(ASX:NOX\)](#) collaborator Hudson Institute of Medical Research has been granted A\$1.45 million from the Victorian Government to fund a joint development program into novel therapeutics to block inflammation.

Pharmorage Pty Ltd, Noxopharm's wholly-owned subsidiary, has been named on the grant as the collaborator to design and synthesise the compounds with the view of commercialising any promising drug candidates generated by the research.

It is hoped that any outcomes of the research will extent Noxopharm's portfolio of anti-inflammatory therapeutics.

Network of collaborators

"Noxopharm has built a network of collaborators spanning world-renowned academic and government institutions, including Hudson Institute," Noxopharm CEO Dr Gisela Mautner said.

"We are excited the collaboration with Hudson Institute is attracting this level of non-dilutive funding. We look forward to progressing our work in inflammatory diseases with them."

The Hudson Institute of Medical Research is a global bioscience medical research leader, aiming to improve human health through collaborative, medical research discoveries and the translation of these to real world impact.

Hudson Institute scientists research five areas of medical need:

- Inflammation

Most read

Mining

[Lake Resources' new chair will ready lithium operations for North America's...](#)

2 days, 23 hours ago

Industry & services

[SpaceX fires at least five employees who said Elon Musk's behaviour is...](#)

2 days, 10 hours ago

Retail & consumer

[Boots sale maybe under threat as buyers struggle to raise capital](#)

2 days, 18 hours ago

Industry & services

[Cazoo Group driving shareholders up the wall](#)

2 days, 12 hours ago



2 MIN READ

[< Prev article](#)

[Next article >](#)

- ▶ Infant and child health
- ▶ Cancer
- ▶ Hormones and health

The research is set to start in the coming weeks and run for about two years.

About the research

The goal of this research is to identify novel drug compounds that dampen harmful excessive inflammation associated with COVID-19 infection.

If any drug candidates show promise of broader inflammatory indications, Noxopharm is likely to investigate their commercial and scientific potential.

Reducing excessive inflammation during COVID-19 infection is a critical part of limiting virus associated hospitalisations, intensive care admissions and deaths.

There is mounting evidence to suggest that chronic inflammation underpins post-infectious syndromes associated with long-COVID, which may impact as many as 60% of COVID-19 patients.

This research aims to fast-track the therapeutic development of new, targeted therapies to help manage acute and chronic inflammation.

About Noxopharm

Noxopharm has three active drug development programs: its lead clinical-stage drug candidate Veyonda® and two innovative technology platforms – Chroma™ (oncology) and Sofra™ (inflammation and autoimmunity), which provide the basis for active development of a growing pipeline of new proprietary drugs.

Noxopharm also has a major shareholding in the US biotech company [Nyrada \(ASX:NYR\)](#) Inc, which is active in the areas of drug development for cardiovascular and neurological diseases.

View Price & Profile

Add related topics to MyProactive

[+ Health](#)

[+ Pharma & Biotech](#)

[+ Small caps](#)

[+ Noxopharm Ltd](#)

[+ OTC Markets quoted](#)

[+ OTCQB quoted](#)



2 MIN READ

[< Prev article](#)

[Next article >](#)

Email address

Sign up for Newsletter

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

Proactive Investors Australia Pty Ltd ACN 132 787 654 (the Company, we or us) provides you with access to the content set out above, including any news, quotes, information, data, text, reports, ratings, opinions,...

FOR OUR FULL DISCLAIMER CLICK HERE

More on this story >



Health

Noxopharm's Veyonda® secures Orphan Drug Designation from US FDA

on 03/21/2022



Health

Noxopharm partner, California's City of Hope Cancer Center, enrolls...

on 02/27/2022



2 MIN READ

< [Prev article](#)

[Next article](#) >

Noxopharm's half-year results include strong cash position and...

on 02/21/2022

Noxopharm retrains focus on pancreatic cancer and ends December on...

on 02/01/2022

Watch >



Sonoro Gold sees strong demand for private placement, increases amount to...

Sonoro Gold CEO Ken Macleod joined Steve Darling from Proactive to share news the company has increased their Private Placement to 2.4 million dollars. Macleod shares with Proactive more about the demand they are seeing especially in tough market conditions. Macleod talks about the work they are...

6 hours, 28 minutes ago



Mining

Electra Battery Materials begin evaluation of second battery...

6 hours, 39 minutes ago



Open Orphan: A London-listed leader clinical challenge studies

17 hours, 56 minutes ago

Mining

Tirupati battled "nature's fury" to exceed production target says...

15 hours, 55 minutes ago



Cypress Development Direct Lithium Extraction returns positive results

1 day, 5 hours ago

Editor's picks



Mining

[ACME Lithium advances drilling program at Clayton Valley Nevada...](#)

10 hours, 6 minutes ago



Mining

[Electra Battery Materials says it is in talks to build new cobalt...](#)

11 hours, 31 minutes ago



Tech

[Guardforce AI expands Robotics-as-a-Service offerings with new...](#)

11 hours, 33 minutes ago



2 MIN READ

[Prev article](#)

[Next article](#)